

Atty. Dkt. No. 039386/0411
Application No. 10/700,314

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-62. (Canceled)

63. (New) An isolated human antibody selected from the group consisting of:

a) a human antibody which specifically binds to a polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:2, wherein the antibody binds to an epitope of a polypeptide consisting of the amino acid sequence of SEQ ID NO:2,

b) a human antibody which specifically binds to a polypeptide consisting essentially of a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:2, wherein the polypeptide has chemotactic activity or is able to activate neutrophils or monocytes, and wherein the antibody binds to an epitope of a polypeptide consisting of a naturally occurring amino acid sequence at least 90% identical to SEQ ID NO:2, and

c) a human antibody which specifically binds to a fragment consisting essentially of at least 9 contiguous amino acids of a polypeptide consisting of the amino acid sequence of SEQ ID NO:2, wherein the fragment has chemotactic activity or is able to activate neutrophils or monocytes.

64. (New) The isolated human antibody of claim 63, wherein said antibody is a neutralizing antibody.

65. (New) The isolated human antibody of claim 63, wherein said antibody is a polyclonal antibody.

66. (New) The isolated human antibody of claim 63, wherein said antibody is a monoclonal antibody.

Atty. Dkt. No. 039386/0411
Application No. 10/700,314

67. (New) A composition comprising an antibody of claim 63 and an acceptable excipient.
68. (New) A composition of claim 67, wherein the antibody is labeled.
69. (New) The composition of claim 67, wherein said label is selected from the group consisting of radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents and magnetic particles.
70. (New) A method for treating inflammation or a disease of the adenoid comprising administering to a subject an effective amount of the composition of claim 67.
71. (New) A method for treating tonsillitis, Epstein-Barr virus, Hodgkin's disease, neoplasms or nonspecific pharyngitis comprising administering to a subject an effective amount of the composition of claim 67.
72. (New) The antibody of claim 66, wherein said antibody has an affinity of at least 10^8 M^{-1} .
73. (New) The antibody of claim 72, wherein said antibody has an affinity of at least 10^9 M^{-1} .
74. (New) The antibody of claim 73, wherein said antibody has an affinity of at least 10^{10} M^{-1} .